United Cannabis (CNABQ) 10-Q 23 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 16, 2016
Document And Entity Information
Entity Registrant Name	United Cannabis Corp
Entity Central Index Key	1,436,161
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		44,988,500
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,016

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 28,298	$ 118,420
Account receivable, net	86,306	53,435
Due from related parties	$ 8,284	8,284
Prepaid expenses		56,341
Deferred financing costs, net	$ 11,572	32,400
Total current assets	134,460	268,880
Intangible assets	32,273	32,273
Investments in non-marketable securities	15,125	205,275
Equity method investments	88,000	88,000
Total assets	269,858	594,428
Current liabilities:
Accounts payable	62,665	104,238
Accrued expenses	281,785	928,533
Derivative liabilities	628,329	383,581
Current portion of deferred revenue	380,000	380,000
Notes payable	615,000	775,000
Convertible notes payable, net of $92,364 and $272,793 debt discount, respectively	311,614	108,207
Total current liabilities	2,279,393	2,679,559
Deferred revenue, net of current portion	338,750	383,750
Total liabilities	$ 2,618,143	$ 3,063,309
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, no par value: 10,000,000 authorized; none issued and outstanding
Common stock, no par value, 100,000,000 shares authorized; 44,988,500 issued and outstanding at March 31, 2016 and December 31, 2015, respectively	$ 3,698,342	$ 3,039,448
Accumulated deficit	(6,046,627)	(5,508,329)
Total stockholders' deficit	(2,348,285)	(2,468,881)
Total liabilities and stockholders' deficit	$ 269,858	$ 594,428

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, no par value
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, no par value
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	44,988,500	44,988,500
Common stock, shares outstanding	44,988,500	44,988,500
Convertible notes payable, debt discount	$ 92,364	$ 272,793

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues
Revenues, non-affiliated	$ 245,390	$ 84,405
Revenues, affiliate		4,425
Total revenues	$ 245,390	88,830
Cost of revenues	(100,023)	(27,055)
Gross profit	145,367	61,775
Operating expenses
General and administrative	(208,170)	(559,162)
Loss from operations	$ (62,803)	(497,387)
Other costs and expenses
Loss on settlement of disputed terms of warrant		$ (768,602)
Loss on derivative liabilities	$ (155,156)
Loss on early extinguishment of debt	(84,139)
Interest expense	(56,581)	$ (19,911)
Amortization of debt discount	$ (179,620)
Equity in net loss of unconsolidated affiliate		$ (50,000)
Loss before provision for taxes on income	$ (538,299)	$ (1,335,900)
Provision for taxes on income
Net Income (Loss)	$ (538,299)	$ (1,335,900)
Basic loss per common share, basic and diluted	$ (0.01)	$ (0.03)
Basic and diluted weighted average number of shares outstanding	44,988,500	44,407,767

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (538,299)	$ (1,335,900)
Increase in accounts receivable	$ (32,871)	(27,604)
Increase in due from related parties		3,112
Increase (decrease) in prepaid expenses	$ 56,341	$ (3,845)
Decrease in deferred financing costs	20,828
Increase (Decrease) in accounts payable and accrued expenses	(1,418)	$ 103,181
Decrease in deferred revenue	(45,000)	$ (45,000)
Amortization of debt discount	179,620
Loss on revaluation of derivative liabilities	155,156
Stock based compensation	46,382	$ 214,037
Loss on early extinguishment of debt	$ 84,139
Loss on settlement of disputed terms of warrant		$ 768,602
Equity in net loss of unconsolidated subsidiary		50,000
Cash used in operations	$ (75,122)	(273,417)
Cash flow from investing activities:
Purchase of intangible assets		(12,385)
Net cash flow used in investing activities		$ (12,385)
Cash flow from financing activities:
Proceeds from convertible note	$ 81,978
Payment of convertible note including prepayment penalty	(81,978)
Payments on notes payable	(15,000)
Net cash flows from financing activities	(15,000)
Net cash flows	(90,122)	$ (285,802)
Cash and cash equivalents, beginning of period	118,420	321,353
Cash and cash equivalents, end of period	$ 28,298	$ 35,551
Supplemental cash flow disclosures
Cash paid for interest
Cash paid for income taxes

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement of Cash Flows [Abstract]
Discount on convertible note		$ 45,000

BUSINESS ORGANIZATION AND NATUR

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS On March 19, 2014, we affected a four-for-one stock split of our outstanding shares of common stock. All references to shares of our common stock in our condensed consolidated financial statements refer to the number of shares of common stock after giving effect to the stock split (unless otherwise indicated). Background and Current Operations United Cannabis Corporation ("we", "our", "us", "UCANN", or “the Company”) a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold to the prior President of the Company. In early 2014 we decided to exit the medical spa management business and change our focus to providing products, services and intellectual property to the cannabis industry. On March 26, 2014, we entered into a License Agreement with Earnest Blackmon, Tony Verzura and Chad Ruby pursuant to which Messrs. Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock. In connection with this transaction: ☐ Messrs. Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid therapy program called "A.C.T. Now", security, regulatory compliance, and other methods and processes which relate to the cannabis industry. ☐ The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement. ☐ Messrs. Blackmon, Verzura and Ruby were appointed to our board of directors effective April 7, 2014. ☐ Mr. Blackmon was elected as our President, Mr. Ruby was elected as Chief Operating Officer and Mr. Verzura was elected as Vice President. ☐ A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014. UCANN was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCANN, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation. On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we have entered into a new business and no longer have any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014. Government Regulation As of March 31, 2016, 23 states and the District of Columbia allow their citizens to use medical marijuana, and voters in the states of Colorado, Washington, Oregon, Alaska and the District of Columbia approved ballot measures to legalize cannabis for adult recreational use. The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The Obama administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical and recreational marijuana. However, there is no guarantee that the current administration will not change its stated policy regarding the low-priority enforcement of federal laws, or that any future administration would not change this policy and decide to enforce the federal laws vigorously. Any such change in the federal government’s enforcement of current federal laws could cause significant financial damage to us.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation Principles of Consolidation Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our condensed consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term. Financial Instruments Financial Instruments The carrying amounts of our short-term financial instruments, including accounts receivable, , accounts payable, accrued expenses and deferred revenue approximates fair value due to the relatively short period to maturity for these instruments. Investments in non-marketable equity securities are carried at cost. The carrying amount of our notes payable at March 31, 2016 and December 31, 2015, approximates their fair values based on our incremental borrowing rates. Cash and Cash Equivalents Accounts Receivable We determine our allowance for doubtful accounts by regularly evaluating individual customer receivables and considering the customer’s financial condition and credit history, and current economic conditions. Our allowance for doubtful accounts was $4,340 as of March 31. 2016 and December 31, 2015, respectively. Intangible Assets – Investments in Non-Marketable Equity Securities Long-Lived Assets Equity Method Investments Deferred Revenue Revenue Recognition - Revenue Recognition Revenue for services with a payment in form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue is measured using the Black-Scholes model for warrants. Cost of Revenues Research and Development Expenses - General and Administrative Expenses - Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation Income Taxes Income Taxes Commitments and Contingencies If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our condensed consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. Net Income Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended March 31, 2016 2015 Warrants to purchase common stock 708,334 3,170,044 Stock options 3,680,000 600,000 Other Comprehensive Income (Loss) Segment Reporting – Concentration of Credit Risk The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Three Months Ended March 31, 2016 2015 Customer A 92 % 51 % Customer B 8 % 26 % Customer C — % 17 % Percentage of Accounts Receivable: Three Months Ended March 31, 2016 2015 Customer A 52 % 68 % Customer B 38 % 30 % Customer C 9 % 21 % Recently Issued Accounting Pronouncements In May 2014 the FASB issued guidance on revenue from contracts with customers, which implements a five step process of how an entity should recognize revenue in order to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective at the beginning of fiscal year 2017, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the impact that the adoption will have on our condensed consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing reporting.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Mar. 31, 2016
GOING CONCERN [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN Our condensed consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the three months ended March 31, 2016, we incurred losses of $538,299 and used cash of $75,122 in operating activities. As at March 31, 2016, we had a working capital deficit of $2,144,125 and an accumulated deficit of $6,046,627. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

INVESTMENTS IN NON-MARKETABLE E

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES	3 Months Ended
	Mar. 31, 2016
Investments, All Other Investments [Abstract]
INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES	NOTE 4 – INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES On June 9, 2014, we received 1,187,500 common shares of WeedMD RX Inc. (“WMD”), a private Canadian company in the cannabis industry, in exchange for future consulting services and use of our intellectual property. The $593,750 cost assigned to the WMD shares was classified as investment in non-marketable equity securities and as a component of deferred revenue in the amount of $593,750 on our condensed consolidated balance sheets. On March 24, 2016, an unrelated third party agreed to assume all of our obligations, including accrued and unpaid interest, pursuant to the terms of a $175,000 note payable we owed to WeedMD, in consideration for the transfer by us of 1,100,000 shares of the common stock of WMD to the unrelated third party. WMD consented to the assumption of the loan by the unrelated third party, and released us from any further liability with respect to the loan. After the exchange of the 1,100,000 shares of common stock of WMD to the unrelated third party, we own to 87,500 shares of common stock of WMD, and reduced our investment in none-marketable equity securities to $15, 125.

PREPAID EXPENSES AND OTHER ASSE

PREPAID EXPENSES AND OTHER ASSETS	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER ASSETS	NOTE 5 – PREPAID EXPENSES AND OTHER ASSETS Prepaid expenses and other assets consist of: March 31, 2016 December 31, 2015 Prepaid investor relations services $ — $ 1,667 Prepaid licensing fees — 35,000 Other prepaid services and fees — 19,674 $ — $ 56,341

INTANGIBLES

INTANGIBLES	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLES	NOTE 6 – INTANGIBLES Our intangible assets are comprised of provisional patent applications and applications for a design mark and trademarks. Our intangible assets will be amortized on a straight-line basis over estimated useful lives of 20 years for patents and 10 years for design marks and trademarks once the applications are approved. Costs associated with applications that are not approved will be expensed in the period that the application is rejected or abandoned.

EQUITY METHOD INVESTMENTS

EQUITY METHOD INVESTMENTS	3 Months Ended
	Mar. 31, 2016
Equity Method Investments and Joint Ventures [Abstract]
EQUITY METHOD INVESTMENTS	NOTE 7 – EQUITY METHOD INVESTMENTS On August 15, 2014, we acquired a 50% interest in Cannabinoid Research & Development Company Limited (“CRD”), a Jamaican company, in exchange 40,000 shares of our common stock valued at $88,000 based on the previous day’s closing price of our stock. We also committed to provide expertise on design-build, genetics, cultivation, production, processing, productizing, labeling, packaging, marketing, branding and distribution of products, as well as use of our intellectual property in the operations of CRD. As of March 31, 2016, CRD did not have any operations or operating activities. We accounted for this $88,000 as an equity method investment on our condensed consolidated balance sheets.

ACCRUED EXPENSES

ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2016
Accrued Liabilities, Current [Abstract]
ACCRUED EXPENSES	NOTE 8 – ACCRUED EXPENSES March 31, 2016 December 31, 2015 Accrued consulting fees $ 110,000 $ 110,000 Accrued wages and related expenses 12,113 629,780 Accrued interest expense 34,387 101,185 Accrued other expenses 67,500 87,568 $ 224,000 $ 928,533 The $110,000 accrued consulting fees at March 31, 2016 and December 31, 2015 represent fees owed to consultants working on a research and development project that is approximately 80% complete.\

FAIR VALUE MEASUREMENTS AND DER

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	NOTE 9 – FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES The following table provides the liabilities carried at fair value measured on a recurring basis as of March 31, 2016 Level 1 Level 2 Level 3 Total Derivative liabilities - convertible notes $ — $ — $ 391,102 $ 391,102 Derivative liabilities - note payable — 145,023 — 145,023 Derivative liabilities - warrants — 92,204 — 92,204 Total $ — $ 237,227 $ 391,102 $ 628,329 Convertible Notes Payable We valued our derivative liabilities related to embedded conversion features applicable to our borrowings of $322,000 under our convertible notes payable with embedded derivative features (see Note 12 below) and accrued interest payable of $9,594 thereon in accordance with fair value measurement guidelines. For the three months ended March 31, 2016, the following table reconciles the beginning and ending balances for our financial instruments that are carried at fair value measured on a recurring basis: Derivative liabilities as of December 31. 2015 $ 383,581 Loss on revaluation of derivative liabilities during the period 70,082 Additions to conversion features recorded as interest expense 7,836 Extinguishment of derivative liabilities associated with payment of convertible note (70,397 ) Derivative liabilities as of March 31, 2016 $ 391,102 The estimated fair value of the derivative liabilities related to our convertible notes payable was measured as the aggregate estimated fair value of each component of the compound embedded derivative liabilities (see Note 12 below), based on Level 2 and Level 3 inputs, using a binomial lattice pricing model. Changes in the fair value of the compound embedded derivative liability at each reporting date are included in gain/ (loss) on derivative liabilities in our consolidated statement of operations.

DEFERRED REVENUE

DEFERRED REVENUE	3 Months Ended
	Mar. 31, 2016
Deferred Revenue Disclosure [Abstract]
DEFERRED REVENUE.	NOTE 10 – DEFERRED REVENUE Our deferred revenue consists of: March 31, 2016 December 31, 2015 Deferred revenue - WeedMD $ 518,750 $ 563,750 Deferred revenue - FoxBarry 200,000 200,000 718,750 763,750 Less - current portion (380,000 ) (380,000 ) Deferred revenue, net of current portion $ 338,750 $ 383,750 As described in Note 4 above, on June 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WMD in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue, and we recognized $150,000 of this amount as revenue during the period July 1, 2014 through December 31, 2014, based upon our initial three year estimate of the service period involved. Based on recent discussions with WMD, we expect to deliver the remaining consulting services and use of our intellectual property to WMD on a relatively consistent monthly basis during the four year period January 1, 2015 through December 31, 2018. Accordingly, we are now recognizing $15,000 of deferred revenue per month, and thus, during the three month period ending March 31, 2016 and 2015, we recognized a total of $45,000 of revenue applicable to this arrangement, respectively. At March 31, 2016, we expect to recognize $180,000 of the remaining $518,750 WMD deferred revenue during the next twelve months and accordingly, we have classified the $180,000 as a current liability on our condensed consolidated balance sheets. On December 28, 2014, we entered into a royalty and consulting services agreement with FoxBarry Farms, LLC (“FoxBarry”) whereby we received a $200,000 prepaid royalty payment from FoxBarry. We will recognize deferred royalty revenue based on actual applicable sales as defined in the agreement. During the three months ended March 31, 2016 and 2015, we did not recognize any deferred revenue related to this agreement. We have classified the $200,000 as a current liability on our condensed consolidated balance sheets as we expect to recognize this amount during the next twelve months.

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Mar. 31, 2016
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 11 – NOTES PAYABLE Our notes payable consisted of the following: March 31, 2016 December 31, 2015 Note payable - WeedMD $ — $ 175,000 Note payable - Slainte Ventures, LLC 600,000 600,000 Note payable – Donaldson Consulting 15,000 — Total notes payable $ 615,000 $ 775,000 On July 7, 2014, we issued a $175,000, unsecured demand promissory note bearing interest at 5% to WeedMD for cash used in our business development activities. As discussed in Note 4 above, on March 24, 2016, an unrelated third party agreed to assume all of our obligations pursuant to the $175,000 note payable to WeedMD, in consideration for the transfer by us of 1,100,000 shares of the common stock of WeedMD to the unrelated third party. WeedMD consented to the assumption of the loan and released us from any further liability with respect to the loan. On December 18, 2014, we issued a $600,000 unsecured promissory note bearing interest at 12% to an unrelated third party, Slainte Ventures, LLC. The principal and accrued interest are due on the earlier of December 17, 2015, or upon the closing of certain capital raising transactions as described in the note. The default rate of interest under the note is 18%. On March 16, 2016, we entered into an agreement with Slainte whereby Slainte waived default, amended the terms and extended the maturity date of the Slainte Note until December 17, 2016, and agreed to accept a warrant in lieu of interest due on the loan. The warrant allows Slainte to purchase 416,667 shares of our common stock; plus that number of shares of our common stock equal in number to (i) the product of the then-applicable interest rate under the Slainte Note and the amount of principal outstanding on the Note, calculated on a daily basis and paid for actual days elapsed, during the period beginning on December 18, 2015, and ending on the date on which the Note is paid in full, divided by (ii) $0.18; plus that number of shares of our common stock equal in number to (i) the product of 0.02 and the sum of the amount of principal and interest outstanding on the Note on the first day of each calendar month, beginning with February 1, 2016, divided by (ii) $0.18. The warrant is exercisable at a price of $0.18 per share, subject to adjustment in the event of stock splits, the sale of our shares of common stock at a price below $0.18 per share or the sale of equity securities with a conversion price of less than $0.18 per share. The warrant can be exercised at any time during the five year period following the full repayment of the loan; the exercise price can be paid in cash or through a cashless exercise feature; and the warrant grants certain registration rights to Slainte applicable to all shares of our common stock owned or controlled by Slainte, including shares issued upon exercise of the warrant. In addition, Slainte granted us a put option, exercisable upon repayment of the loan prior to December 17, 2016, that requires Slainte to purchase from us, for $100,000, that number of shares of our common stock equal in number to (i) $100,000 divided by (ii) the product of 80% and the average price of our common stock for the 30 trading days immediately prior to the date the put option is exercised. These warrants are accounted for as a liability under ASC 815. The Company assesses the fair value of the warrants quarterly based on the Black-Scholes pricing model. See below for variables used in assessing the fair value. March 16, 2016 March 31, 2016 Expected life (years) 5.0 4.96 Risk-free interest rate 1.41 % 1.21 % Expected volatility 226 % 227 % In connection with these warrants, the Company recognized a loss on the change in fair value of warrant liability of $229,609 during the three months ended March 31, 2016. Expected volatility is based primarily on historical volatility. Historical volatility was computed using weekly pricing observations for recent periods that correspond to the expected life of the warrants. The Company believes this method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants. The Company currently has no reason to believe future volatility over the expected remaining life of these warrants is likely to differ materially from historical volatility. The expected life is based on the remaining term of the warrants. The risk-free interest rate is based on U.S. Treasury securities rates. Due to the fair value of the warrants issued in connection with the amended note agreement, the modification was considered substantial (i.e. greater than 10% of the carrying value of the debt). As a result, an extinguishment of debt was deemed to have occurred, resulting in the recognition of an extinguishment loss of $133,077.

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	3 Months Ended
	Mar. 31, 2016
CONVERTIBLE NOTE PAYABLE [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 12 – CONVERTIBLE NOTES PAYABLE 2015 Convertible Notes During the year ended 2015, we issued three convertible promissory notes to unaffiliated third parties. The net proceeds from these transactions were are used for general working capital purposes. During the three months ended March 31, 2016 we issued one convertible promissory note, the net proceeds from which was used to pay the principal and accrued interest of one of the convertible notes issued during the year ended December 31, 2015. The difference between the face amount of the convertible notes and the net proceeds was recorded as deferred financing costs on our consolidated balance sheets if such difference was the result of payments related to debt issuance costs. Any deferred financing costs are amortized on a straight-line basis, which approximates the effective interest rate method, during the first 180 days that the convertible notes are outstanding, and this amortization is included in interest expense in our consolidated statements of operations. The following table summarizes our convertible promissory notes as of March 31, 2016: Issue Date Issued To Maturity Date Interest Rate Default Rate Base Conversion Rate VCR Look Back Period VCR Calculated Using Principal Balance 10/12/15 SJS Investments Unsecured 7/8/16 12 % 18 % 55 % 10 Days 5 Lowest trades $ 102,000 12/9/15 Tangiers Investment Group Secured by Certain Assets 12/8/16 10 % 20 % 55 % 10 Days 3 lowest closing bids 220,000 3/30/16 Slainte Ventures Unsecured 12/30/16 12 % Mandatory Conversion N/ A 10 Days 10 day average 81,978 $ 403,978 The convertible notes, including accrued interest payable, may be converted into shares of our common stock at the Conversion Price, as defined below, in whole, or in part, at any time beginning 180 days after the date of issuance, at the option of the holder (the “Conversion Feature”). The Conversion Price is equal the Base Conversion Rate specified in the table above multiplied by the Variable Conversion Rate (“VCR”) which is equal to the average of the number of lowest trading prices or closing bid prices of our common stock (specified in the table above) during the ten trading day period prior to the date of conversion divided by the closing price of our common stock on the day of conversion. Both of these conversion rates results in a beneficial conversion features (“BCF”) recorded as unamortized convertible debt discount which is required to be valued and amortized to interest expense over the term of the Note. We amortize our convertible debt discount on a straight-line basis, which approximates the effective interest rate method, during the first 180 days that each Note is outstanding and this amortization is included in amortization of debt discount in our consolidated statements of operations. If a Note is repaid during the first 180 days, the remaining unamortized deferred financing costs and unamortized debt discount are expensed on the date of repayment. The convertible notes are convertible into an unlimited number of unregistered, restricted common shares (“Unlimited Shares Feature”). The difference between the closing price of our common stock and the VCR is referred to as the Variable Conversion Rate Differential (“VCRD”). Both the Unlimited Shares Feature and the VCRD meet the definition of an embedded derivative and together are referred to as a compound embedded derivative liability or, hereafter, simply a “derivative liability.” In accordance with U.S. GAAP, our derivative liabilities are recorded at fair value on the date of issuance and subsequently remeasured to fair value each reporting period with any change in fair value being recognized as gain (loss) on derivative liabilities in our consolidated statement of operations. Similarly, accrued interest payable applicable to the Notes is convertible into shares of our common stock, without limit, at the same Conversion Price. The fair value of the derivative liabilities applicable to accrued interest payable is measured and recognized at each reporting date as derivative liabilities with a corresponding charge to interest expense. As noted above, all derivative liabilities are re-measured in subsequent reporting periods with any change in fair value being included in gain (loss) on derivative liabilities. The Notes also contain prepayment options whereby we may, during the first 180 days that each note is outstanding, prepay the note by paying prepayment premiums ranging from 10% to 40% of the principal then outstanding depending on the date of prepayment. In general, per the terms of our convertible notes. The note holders may not make any conversions that would result in the note holder holding more than 9.99% of our issued and outstanding common stock at any one time. At March 31, 2016, we have reserved 10.2 million shares of our authorized but unissued common stock for potential conversion of the convertible notes. Should we default on a conversion or repayment of a convertible notes, the note, accrued interest and default penalties and fees are immediately due and payable. The minimum default penalty amount ranges from 25% to 50% (or more, under certain circumstances) times the then outstanding principal and unpaid interest. As of December 31, 2015, we had unamortized deferred financing fees of $32,400 outstanding in connection with the issuance of our convertible notes. During the three months ended March 31, 2016, we recognized $20,827 of amortization of deferred financing costs. This amount is included in interest expense in our consolidated statements of operations. The aggregate fair value of the derivative liabilities applicable to our convertible notes on the dates of issuance was $355,293, and was recorded as derivative liabilities on our consolidated balance sheets. The related BCF debt discount was recorded as a reduction to our convertible notes payable on our consolidated balance sheets. During the three months ended March 31, 2016, we recognized $179,620 of amortization related to the convertible notes and recorded this amount as amortization of debt discount in our consolidated statements of operations. We recognized $9,628 of interest expense applicable to our convertible notes during the three months ended March 31, 2016, and included this amount of accrued interest payable as accrued expenses on our consolidated balance sheets. Slainte Convertible Note On March 30, 2016, we borrowed $81,978, from Slainte and used the proceeds to repay principal and accrued interest applicable to our $59,000 convertible promissory note dated October 6, 2015, to Vis Vires Group, Inc. The loan, together with interest at 12% per year, is payable on December 30, 2016. We can prepay the loan at any time. If the loan is repaid on or before September 30, 2016, the principal amount which is being repaid will increase by 10%. If the loan is repaid after September 30, 2016, the principal amount which is being repaid will increase by 15%. The amount of the principal increase may be paid with shares of our common stock. The number of shares to be issued for such purpose will be determined by dividing the average closing price of our common stock (which in no case can be greater than $0.45) for the ten trading days preceding the prepayment date. If the loan is not paid when due, then at any time on or before January 10, 2017, Slainte may convert the outstanding principal and interest on the loan into shares of our common stock. The number of shares to be issued on conversion will be determined by dividing the average closing price of our common stock (which in no case can be greater than $0.45) for the ten trading days preceding the conversion date by the outstanding principal and interest on the loan on the conversion date.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	3 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 13 – STOCKHOLDERS’ DEFICIT Stock Options On January 9, 2015, we awarded 200,000 stock options to each of Messrs. Blackmon, Verzura and Ruby under our 2014 Stock Incentive Plan. The options were fully vested at the time of grant and give the option holder the right to purchase shares of our common stock at $0.70 per share during the ten year term of the option. We calculated the fair value of each option to be approximately $0.70 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.70 Exercise price $ 0.70 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 % At December 31, 2015, the fair value of these 600,000 options totaling $417,664 was included in accrued expenses on our condensed consolidated balance sheets and on January 9, 2015, the option grant date, we increased common stock and decreased accrued expenses by this amount to account for the issuance of these options on that date. On January 12, 2016, we awarded 1,050,000 stock options to each of Messrs. Blackmon, Verzura and 980,000 stock potions to Mr. Ruby under our 2014 Stock Incentive Plan. The options were fully vested at the time of grant and give the option holder the right to purchase shares of our common stock at $0.20 per share during the ten year term of the option. We calculated the fair value of each option to be approximately $0.20 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.20 Exercise price $ 0.20 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 % At December 31, 2015 the fair value of these 3,080,000 options totaling $612,512, which was included in accrued expenses on our condensed consolidated balance sheets, and on January 15, 2016, the option grant date, we increased common stock and decreased accrued expenses by this amount to account for the issuance of these options on that date. The following table summarizes our stock options outstanding as of March 31, 2016: Three Months Ended March 31, 2016 Number of Shares Weighted Average Remaining Life (years) Weighted Average Exercise Price Stock options outstanding, beginning of period 600,000 9.8 $ 0.70 Issued 3,080,000 10.0 0.20 Exercised — — — Expired — — — Stock options outstanding, end of period 3,680,000 9.6 $ 0.26 Stock options exercisable, March 31, 2016 3,680,000 9.6 $ 0.26 Common Stock Issued For Warrant Outstanding On February 10, 2015, we issued 621,000 shares of our common stock valued at $987,390 based on the previous day’s closing price, to Typenex Co-Investment, LLC ("Typenex") in exchange for the return of Warrant #1 to Purchase Shares of Common Stock (the “Warrant”) that we issued to Typenex on August 13, 2014, as part of a financing arrangement. On February 10, 2015, we calculated the fair value of the Warrant to be $218,788, or approximately $1.29 per underlying share, utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 1.59 Exercise price $ 3.00 Risk free interest rate 1.05 % Expected term (years) 2.6 Expected volatility 183 % Expected dividends 0 % The Warrant gave Typenex the right to purchase 170,044 shares of our common stock on the issuance date and provided for adjustments to the number of shares underlying the Warrant upon occurrence of certain events including subsequent sales of our common stock. Our repurchase of the Warrant resulted in Typenex forgoing its potential right to receive shares in excess of the original 170,044 shares underlying the Warrant on the original issuance date. On February 10, 2015, we recorded the $768,602 fair value of the common shares issued in excess of the $218,788 fair value of the Warrant reacquired as a loss on settlement of disputed terms of warrant in our condensed consolidated statements of operations and as an increase in common stock on our condensed consolidated balance sheets. On February 10, 2015, we cancelled the Warrant and recorded the $218,788 fair value as an increase to common stock. Common Stock Issued For Services On March 2, 2015, we issued 30,000 shares of common stock valued at $42,600, based on the previous trading day’s closing price, as consideration for consulting services from an independent contractor. The $42,600 is included in included in general and administrative expense in our condensed consolidated statements of operations. Warrants: The following table summarizes our share warrants outstanding as of March 31, 2016 and December 31, 2015: Three Months Ended March 31, 2016 Number of Shares Weighted Average Remaining Life (years) Weighted Average Exercise Price Warrants outstanding, December 31, 2015 3,000,000 1 $ 12.00 Issued 708,334 5 0.18 Issuable under terms of the amended Slainte note payable 265,914 Exercised — — — Expired (3,000,000 ) — — Warrants outstanding, end of period 974,248 4.95 $ 0.18 Warrants exercisable, March 31, 2016 974,248 4.95 $ 0.18

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	NOTE 14 – SHARE-BASED COMPENSATION Share-based Compensation We recognize share-based compensation expense in cost of revenues and general and administrative expense based on the fair value of common shares issued for services. Share-based compensation expense for the three months ended March 31, 2016 and 2015 is as follows: Three Months Ended March 31, 2016 2015 Share-based compensation expense – shares issued for consulting services $ 46,382 $ 42,600 Share-based compensation expense – amortization of shares issued for prepaid services — 66,437 Share-based compensation expense – accrual of estimated share-based awards — 105,000 $ 46,382 $ 214,037

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 15 –COMMITMENTS AND CONTINGENCIES Contractual Obligations and Commercial Commitments On February 20, 2016, we entered into a consulting agreement with a third party that has a twelve month term, and which can be extended by mutual agreement. The agreement provides for the issuance of a five (5) year warrant to the consultant, upon the execution of the agreement, to purchase 250,000 shares of our common stock at a price of $0.18 per share, plus the payment of $7,500 on the first day of each month, beginning March 1, 2016, coupled with the monthly issuance of five (5) year warrants to purchase our common stock in an amount of shares determined by dividing $7,500 by $0.18 per share. These warrants are exercisable at a price of $0.18 per share. During the three months ended March 31, 2016, we recognized $46,382 of expense applicable to this consulting agreement. On May 6, 2014, we entered into a consulting agreement with two third party consultants that has a nine month term, which can be renewed and/or extended by mutual agreement. Currently, the renewal of the agreement is under negotiation. The agreement provides for a $50,000 payment to the consultants at signing, which has been paid, and for three more $50,000 payments (a total of $200,000) and the issuance of 100,000 During the years ended December 31, 2015 and 2014, we recognized $0 and $160,000 of expense applicable to this agreement and this amount is included in R&D expenses in our consolidated statements of operations. At March 31, 2016 and December 31, 2015 the project was approximately 80% complete and $110,000 is included in accrued expenses on our consolidated balance sheets. The value of the 100,000 shares will be recognized upon achievement of the goals. The project has been suspended and it is unknown when it will resume. Legal Proceedings We were not subject to any legal proceedings during the three months ended March 31, 2016, and, to the best of our knowledge, no legal proceedings are pending or threatened.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16 – SUBSEQUENT EVENTS On April 6, 2016, we borrowed $75,000, from Slainte Ventures, LLC, and used the proceeds to repay a portion of the principal and accrued interest applicable to our $102,000 convertible promissory note dated October 12, 2015, to JSJ Investments Inc.The loan, together with interest at 12% per year, is payable on December 30, 2016. We may prepay the loan at any time. If the loan is repaid on or before September 30, 2016 the principal amount which is being repaid will increase by 10%. If the loan is repaid after September 30, 2016 the principal amount which is being repaid will increase by 15%. The amount of the principal increase may be paid with shares of our common stock. The number of shares to be issued for such purpose will be determined by dividing the average closing price of our common stock (which in no case can be greater than $0.45) for the ten trading days preceding the prepayment date. If the loan is not paid when due, then at any time on or before January 10, 2017, Slainte may convert the outstanding principal and interest on the loan into shares of our common stock. The number of shares to be issued on conversion will be determined by dividing the average closing price of our common stock (which in no case can be greater than $0.45) for the ten trading days preceding the conversion date by the outstanding principal and interest on the loan on the conversion date. On April 6, 2016, we borrowed $25,000 from Ernest Blackmon and $25,000 from Tony Verzura and used the proceeds to repay a portion of the principal and interest applicable to our $102,000 convertible promissory note dated October 12, 2015, to JSJ Investments Inc. The loans, together with interest at 12% per year, are payable on December 30, 2016. We may prepay the loans at any time. If the loans are repaid on or before September 30, 2016, the principal amount which is being repaid will increase by 10%. If the loans are repaid after September 30, 2016, the principal amount which is being repaid will increase by 15%. In accordance with ASC 855-10 we have analyzed our operations subsequent to March 31, 2016, to the date these condensed consolidated financial statements were issued, and have determined that, other that as disclosed above, we do not have any material subsequent events to disclose in these condensed financial statements.

SUMMARY OF SIGNIFICANT ACCOUN23

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our condensed consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
Financial Instruments	Financial Instruments Financial Instruments The carrying amounts of our short-term financial instruments, including accounts receivable, , accounts payable, accrued expenses and deferred revenue approximates fair value due to the relatively short period to maturity for these instruments. Investments in non-marketable equity securities are carried at cost. The carrying amount of our notes payable at March 31, 2016 and December 31, 2015, approximates their fair values based on our incremental borrowing rates.
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable We determine our allowance for doubtful accounts by regularly evaluating individual customer receivables and considering the customer’s financial condition and credit history, and current economic conditions. Our allowance for doubtful accounts was $4,340 as of March 31. 2016 and December 31, 2015, respectively.
Intangible Assets	Intangible Assets –
Investments in Non-Marketable Equity Securities	Investments in Non-Marketable Equity Securities
Long-Lived Assets	Long-Lived Assets
Equity Method Investments	Equity Method Investments
Deferred Revenue	Deferred Revenue
Revenue Recognition	Revenue Recognition - Revenue Recognition Revenue for services with a payment in form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue is measured using the Black-Scholes model for warrants.
Cost of Revenues	Cost of Revenues
Research and Development Expenses	Research and Development Expenses -
General and Administrative Expenses	General and Administrative Expenses
Share-Based Compensation	Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation
Income Taxes	Income Taxes Income Taxes
Commitments and Contingencies	Commitments and Contingencies If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our condensed consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
Net Income Loss Per Share	Net Income Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended March 31, 2016 2015 Warrants to purchase common stock 708,334 3,170,044 Stock options 3,680,000 600,000
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss)
Segment Reporting	Segment Reporting –
Concentration of Credit Risk	Concentration of Credit Risk The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Three Months Ended March 31, 2016 2015 Customer A 92 % 51 % Customer B 8 % 26 % Customer C — % 17 % Percentage of Accounts Receivable: Three Months Ended March 31, 2016 2015 Customer A 52 % 68 % Customer B 38 % 30 % Customer C 9 % 21 %
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014 the FASB issued guidance on revenue from contracts with customers, which implements a five step process of how an entity should recognize revenue in order to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective at the beginning of fiscal year 2017, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the impact that the adoption will have on our condensed consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing reporting.

SUMMARY OF SIGNIFICANT ACCOUN24

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Schedule of potentially dilutive securities that have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive	Three Months Ended March 31, 2016 2015 Warrants to purchase common stock 708,334 3,170,044 Stock options 3,680,000 600,000
Schedule of significant concentrations in revenues and accounts receivable	Percentage of Revenue: Three Months Ended March 31, 2016 2015 Customer A 92 % 51 % Customer B 8 % 26 % Customer C — % 17 % Percentage of Accounts Receivable: Three Months Ended March 31, 2016 2015 Customer A 52 % 68 % Customer B 38 % 30 % Customer C 9 % 21 %

PREPAID EXPENSES AND OTHER AS25

PREPAID EXPENSES AND OTHER ASSETS (Tables)	3 Months Ended
	Mar. 31, 2016
Prepaid Expense, Current [Abstract]
Schedule of prepaid expenses and other assets	March 31, 2016 December 31, 2015 Prepaid investor relations services $ — $ 1,667 Prepaid licensing fees — 35,000 Other prepaid services and fees — 19,674 $ — $ 56,341

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2016
Accrued Liabilities, Current [Abstract]
Schedule of accrued expenses	March 31, 2016 December 31, 2015 Accrued consulting fees $ 110,000 $ 110,000 Accrued wages and related expenses 12,113 629,780 Accrued interest expense 34,387 101,185 Accrued other expenses 67,500 87,568 $ 224,000 $ 928,533

FAIR VALUE MEASUREMENTS AND D27

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of liabilities carried at fair value measured on a recurring basis	Level 1 Level 2 Level 3 Total Derivative liabilities - convertible notes $ — $ — $ 391,102 $ 391,102 Derivative liabilities - note payable — 145,023 — 145,023 Derivative liabilities - warrants — 92,204 — 92,204 Total $ — $ 237,227 $ 391,102 $ 628,329
Schedule of reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis	Derivative liabilities as of December 31. 2015 $ 383,581 Loss on revaluation of derivative liabilities during the period 70,082 Additions to conversion features recorded as interest expense 7,836 Extinguishment of derivative liabilities associated with payment of convertible note (70,397 ) Derivative liabilities as of March 31, 2016 $ 391,102

DEFERRED REVENUE (Tables)

DEFERRED REVENUE (Tables)	3 Months Ended
	Mar. 31, 2016
Deferred Revenue Disclosure [Abstract]
Schedule of deferred revenue	March 31, 2016 December 31, 2015 Deferred revenue - WeedMD $ 518,750 $ 563,750 Deferred revenue - FoxBarry 200,000 200,000 718,750 763,750 Less - current portion (380,000 ) (380,000 ) Deferred revenue, net of current portion $ 338,750 $ 383,750

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Payable [Abstract]
Schedule of notes payable	March 31, 2016 December 31, 2015 Note payable - WeedMD $ — $ 175,000 Note payable - Slainte Ventures, LLC 600,000 600,000 Note payable – Donaldson Consulting 15,000 — Total notes payable $ 615,000 $ 775,000
Schedule of variables used in assessing fair value	March 16, 2016 March 31, 2016 Expected life (years) 5.0 4.96 Risk-free interest rate 1.41 % 1.21 % Expected volatility 226 % 227 %

CONVERTIBLE NOTE PAYABLE (Table

CONVERTIBLE NOTE PAYABLE (Tables)	3 Months Ended
	Mar. 31, 2016
CONVERTIBLE NOTE PAYABLE [Abstract]
Schedule of convertible promissory notes	Issue Date Issued To Maturity Date Interest Rate Default Rate Base Conversion Rate VCR Look Back Period VCR Calculated Using Principal Balance 10/12/15 SJS Investments Unsecured 7/8/16 12 % 18 % 55 % 10 Days 5 Lowest trades $ 102,000 12/9/15 Tangiers Investment Group Secured by Certain Assets 12/8/16 10 % 20 % 55 % 10 Days 3 lowest closing bids 220,000 3/30/16 Slainte Ventures Unsecured 12/30/16 12 % Mandatory Conversion N/ A 10 Days 10 day average 81,978 $ 403,978

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	3 Months Ended
	Mar. 31, 2016
Summary of share warrants outstanding	Three Months Ended March 31, 2016 Number of Shares Weighted Average Remaining Life (years) Weighted Average Exercise Price Stock options outstanding, beginning of period 600,000 9.8 $ 0.70 Issued 3,080,000 10.0 0.20 Exercised — — — Expired — — — Stock options outstanding, end of period 3,680,000 9.6 $ 0.26 Stock options exercisable, March 31, 2016 3,680,000 9.6 $ 0.26
Summary of stock options outstanding	Three Months Ended March 31, 2016 Number of Shares Weighted Average Remaining Life (years) Weighted Average Exercise Price Warrants outstanding, December 31, 2015 3,000,000 1 $ 12.00 Issued 708,334 5 0.18 Issuable under terms of the amended Slainte note payable 265,914 Exercised — — — Expired (3,000,000 ) — — Warrants outstanding, end of period 974,248 4.95 $ 0.18 Warrants exercisable, March 31, 2016 974,248 4.95 $ 0.18
Stock Options [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	We calculated the fair value of each option to be approximately $0.70 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.70 Exercise price $ 0.70 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 % We calculated the fair value of each option to be approximately $0.20 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.20 Exercise price $ 0.20 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 %
Common Stock Issued for Warrant Outstanding [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	Stock price $ 1.59 Exercise price $ 3.00 Risk free interest rate 1.05 % Expected term (years) 2.6 Expected volatility 183 % Expected dividends 0 %

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of share-based compensation expense	Three Months Ended March 31, 2016 2015 Share-based compensation expense – shares issued for consulting services $ 46,382 $ 42,600 Share-based compensation expense – amortization of shares issued for prepaid services — 66,437 Share-based compensation expense – accrual of estimated share-based awards — 105,000 $ 46,382 $ 214,037

BUSINESS ORGANIZATION AND NAT33

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS (Details) - USD ($)	1 Months Ended
	Mar. 31, 2014	Mar. 31, 2016	Dec. 31, 2015	Mar. 26, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Amount of payable owed to former officer and director, exchanged for assets sold	$ 15,000
Number of common shares issued in exchange for certain intellectual property	38,690,000
Total number of common shares previously outstanding, cancelled during period				41,690,000
Common stock, shares outstanding		44,988,500	44,988,500	43,620,000

SUMMARY OF SIGNIFICANT ACCOUN34

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	3 Months Ended
	Mar. 31, 2016USD ($)Item	Dec. 31, 2015USD ($)
Property, Plant and Equipment [Line Items]
Cash equivalents
Number of operating segment | Item	1
Allowance for doubtful accounts	$ 4,340	$ 4,340
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Equity Method Investments, Percentage	20.00%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	20 years
Equity Method Investments, Percentage	50.00%

SUMMARY OF SIGNIFICANT ACCOUN35

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of anti-dilutive securities) (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	708,334	3,170,044
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	3,680,000	600,000

SUMMARY OF SIGNIFICANT ACCOUN36

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of concentration of credit risk) (Details)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	92.00%	51.00%
Revenue [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	8.00%	26.00%
Revenue [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage		17.00%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	38.00%	30.00%
Accounts Receivable [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	9.00%	21.00%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	52.00%	68.00%

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
GOING CONCERN [Abstract]
Net loss (income)	$ 538,299	$ 1,335,900
Net cash used in operating activities	75,122	$ 273,417
Working capital deficit	2,144,125
Accumulated deficit	$ 6,046,627		$ 5,508,329

INVESTMENTS IN NON-MARKETABLE38

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Narrative) (Details) - USD ($)	Jun. 09, 2014	Mar. 31, 2016	Mar. 24, 2016	Dec. 31, 2015
Schedule of Cost-method Investments [Line Items]
Investments in non-marketable equity securities		$ 15,125		$ 205,275
Notes payable		615,000		775,000
Investments in private securities		15,125		$ 205,275
WeedMD RX Inc. (''WMD'') [Member]
Schedule of Cost-method Investments [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500
Investments in non-marketable equity securities		$ 593,750	$ 15,125
Sale of common stock		1,100,000
Notes payable		$ 175,000
Investments in private securities		$ 593,750	$ 15,125
Shares of investment owned			87,500

PREPAID EXPENSES (Details)

PREPAID EXPENSES (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid investor relations services		$ 1,667
Prepaid licensing fees		35,000
Other prepaid services and fees		19,674
Total prepaid expenses		$ 56,341

INTANGIBLES (Details)

INTANGIBLES (Details)	3 Months Ended
	Mar. 31, 2016
Design Marks and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	10 years
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	20 years

EQUITY METHOD INVESTMENTS (Narr

EQUITY METHOD INVESTMENTS (Narrative) (Details) - USD ($)	Aug. 15, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Equity method investments		$ 88,000		$ 88,000
Due from related parties		$ 8,284		$ 8,284
Equity in net loss of unconsolidated affiliate			$ (50,000)
CRD [Member]
Schedule of Equity Method Investments [Line Items]
Interest acquired (as a percentage)	50.00%
Equity method investments	$ 88,000
Shares of common stock issuable for acquisition of interest	40,000

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Accrued consulting fees	$ 110,000	$ 110,000
Accrued wages and related expenses	12,113	629,780
Accrued interest expense	34,387	101,185
Accrued other expenses	67,500	87,568
Total accrued expenses	$ 224,000	$ 928,533

FAIR VALUE MEASUREMENTS AND D43

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Schedule of fair value measured on a recurring basis) (Details)	Dec. 31, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 383,581
Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	92,204
Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	391,102
Note payable [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 145,023
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Level 1 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Level 1 [Member] | Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Level 1 [Member] | Note payable [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 237,227
Level 2 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 92,204
Level 2 [Member] | Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Level 2 [Member] | Note payable [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 145,023
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 391,102
Level 3 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Level 3 [Member] | Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 391,102
Level 3 [Member] | Note payable [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities

FAIR VALUE MEASUREMENTS AND D44

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Schedule of reconciliation of beginning and ending balances) (Details)	3 Months Ended
	Mar. 31, 2016USD ($)
Reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis
Derivative liability at the beginning of the period	$ 383,581
Convertible Notes Payable [Member]
Reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis
Derivative liability at the beginning of the period	383,581
Loss on revaluation of derivative liabilities during the period	70,082
Additions to conversion features recorded as interest expense	7,836
Extinguishment of derivative liabilities associated with payment of convertible note	(70,397)
Derivative liability at the end of the period	$ 391,102

FAIR VALUE MEASUREMENTS AND D45

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Narrative) (Details) - Convertible Notes Payable [Member]	Mar. 31, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument initial borrowing	$ 322,000
Accrued interest payable	$ 9,594

DEFERRED REVENUE (Details)

DEFERRED REVENUE (Details) - USD ($)	Jun. 09, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 28, 2014
Deferred Revenue Arrangement [Line Items]
Deferred revenue		$ 718,750			$ 763,750
Less - current portion		(380,000)			(380,000)
Deferred revenue, net of current portion		338,750			383,750
WeedMD RX Inc. (''WMD'') [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue		518,750			563,750
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500
Warrants received in exchange for future consulting services and use of our intellectual property	3,000,000
Fair value of securities recorded as deferred revenue	$ 893,750
Deferred revenue recognized per month		15,000
Total deferred revenue recognized		45,000	$ 45,000	$ 150,000	180,000
Fox Barry Farms Llc [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue		$ 200,000			$ 200,000
Prepaid royalty payment						$ 200,000

NOTES PAYABLE (Schedule of Note

NOTES PAYABLE (Schedule of Notes Payable) (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Short-term Debt [Line Items]
Notes payable	$ 615,000	$ 775,000
WeedMD RX Inc. (''WMD'') [Member]
Short-term Debt [Line Items]
Notes payable	$ 175,000
Notes Payable [Member] | WeedMD RX Inc. (''WMD'') [Member]
Short-term Debt [Line Items]
Notes payable		175,000
Notes Payable [Member] | SlainteVentures, LLC [Member]
Short-term Debt [Line Items]
Notes payable	$ 600,000	$ 600,000
Notes Payable [Member] | Donaldson Consulting [Member]
Short-term Debt [Line Items]
Notes payable	$ 15,000

NOTES PAYABLE (Schedule of key

NOTES PAYABLE (Schedule of key inputs in valuation) (Details)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Notes Payable [Abstract]
Expected life (years)	5 years	4 years 11 months 16 days
Risk-free interest rate	1.41%	1.21%
Expected volatility	226.00%	227.00%

NOTES PAYABLE (Narrative) (Deta

NOTES PAYABLE (Narrative) (Details) - USD ($)	1 Months Ended			3 Months Ended
	Dec. 17, 2016	Mar. 30, 2016	Jul. 31, 2014	Mar. 31, 2016	Mar. 16, 2016	Dec. 18, 2015	Dec. 18, 2014	Jul. 07, 2014
Short-term Debt [Line Items]
Loss on the change in fair value of warrant liability				$ 229,609
Recognition of an extinguishment loss				$ 133,077
SlainteVentures, LLC [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate						18.00%
Number of shares called by warrants					416,667
Warrant exercise price				$ 0.18
Warrant Term				5 years
Default rate of interest under the note						80.00%
Proceeds from debt, net		$ 81,978
SlainteVentures, LLC [Member] | Forecast [Member]
Short-term Debt [Line Items]
Value of shares of common stock issued	$ 100,000
Number of trading days	30 days
Notes Payable [Member] | WeedMD RX Inc. (''WMD'') [Member]
Short-term Debt [Line Items]
Debt instrument, face amount								$ 175,000
Debt instrument, interest rate								5.00%
Number of shares of common stock issued			1,100,000
Notes Payable [Member] | Unrelated Third Party [Member]
Short-term Debt [Line Items]
Debt instrument, face amount							$ 600,000
Debt instrument, interest rate							12.00%
Default rate of interest under the note							18.00%

CONVERTIBLE NOTES PAYABLE (Summ

CONVERTIBLE NOTES PAYABLE (Summary of Convertible Promissory Notes Issued) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Total principal outstanding		$ 381,000
SJS Investments Inc. [Member] | 2015 Convertible Notes [Member]
Issue Date	Oct. 12, 2015
Maturity Date	Jul. 8, 2016
Interest Rate	12.00%
Default Interest Rate	18.00%
Base Conversion Rate	55.00%
VCR Look back Period	10 days
VCR Calculated Using	5 lowest trades
Total principal outstanding	$ 102,000
Tangiers Investment Group, LLC [Member] | 2015 Convertible Notes [Member]
Issue Date	Dec. 9, 2015
Maturity Date	Dec. 8, 2016
Interest Rate	10.00%
Default Interest Rate	20.00%
Base Conversion Rate	55.00%
VCR Look back Period	10 days
VCR Calculated Using	3 lowest closing bids
Total principal outstanding	$ 220,000
Slainte Ventures [Member] | 2015 Convertible Notes [Member]
Issue Date	Mar. 30, 2016
Maturity Date	Dec. 30, 2016
Interest Rate	12.00%
VCR Look back Period	10 days
VCR Calculated Using	10 day average

CONVERTIBLE NOTE PAYABLE (Narra

CONVERTIBLE NOTE PAYABLE (Narrative) (Details) - USD ($)	1 Months Ended				3 Months Ended		12 Months Ended
	Dec. 30, 2016	Dec. 17, 2016	Mar. 31, 2016	Mar. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Sep. 30, 2016	Dec. 18, 2015
Debt Instrument [Line Items]
Debt discount amortization and interest expense					$ 179,620
Deferred financing fees			$ 11,572		11,572		$ 32,400
2015 Convertible Notes [Member]
Debt Instrument [Line Items]
Number of trading days immediately preceding the applicable conversion							180 days
Holding rate of issued and outstanding common stock							9.99%
Authorized but unissued common stock							10,200,000
Debt discount amortization and interest expense					179,620
Deferred financing fees							$ 32,400
Amortization of deferred financing costs							20,827
Aggregate fair value of the derivative liabilities							$ 355,293
Accrued interest payable			9,628		$ 9,628
2015 Convertible Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Minimum default penalty amount, rate							25.00%
Prepayment premiums							10.00%
2015 Convertible Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Minimum default penalty amount, rate							50.00%
Prepayment premiums							40.00%
Subsequent Event [Member] | Forecast [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	12.00%							22.00%
Number of trading days	10 days
Average closing price of common stock	$ 0.45
SlainteVentures, LLC [Member]
Debt Instrument [Line Items]
Proceeds from debt, net				$ 81,978
Debt instrument, interest rate									18.00%
SlainteVentures, LLC [Member] | Forecast [Member]
Debt Instrument [Line Items]
Number of trading days		30 days
SlainteVentures, LLC [Member] | Vis Vires Group, Inc. [Member]
Debt Instrument [Line Items]
Repayment of principal and accrued interest			$ 59,000

STOCKHOLDERS' DEFICIT (Schedule

STOCKHOLDERS' DEFICIT (Schedule of Assumptions on Date of Valuation Utilizing for Fair Value of Warrants) (Details) - $ / shares	Jan. 12, 2016	Feb. 10, 2015	Mar. 31, 2016
Warrants price (on dollars per shares)		$ 1.29
Stock price (in dollars per share)		1.59
Exercise price (in dollars per share)		$ 3
Risk free interest rate (as a percent)		1.05%
Expected term (years)		2 years 7 months 6 days
Expected volatility (as a percent)		183.00%
Expected dividends (as a percent)		0.00%
Stock Options [Member]
Warrants price (on dollars per shares)	$ 0.20		$ 0.70
Stock price (in dollars per share)	0.20		0.70
Exercise price (in dollars per share)	$ 0.20		$ 0.70
Risk free interest rate (as a percent)	1.98%		1.98%
Expected term (years)	10 years		10 years
Expected volatility (as a percent)	173.00%		173.00%
Expected dividends (as a percent)	0.00%		0.00%

STOCKHOLDERS' DEFICIT (Stock Op

STOCKHOLDERS' DEFICIT (Stock Option Activity) (Narrative) (Details) - USD ($)	Mar. 31, 2016	Jan. 12, 2016	Dec. 31, 2015	Jan. 12, 2015	Jan. 09, 2015
2014 Stock Incentive Plan [Member]
Awarded stock options					$ 200,000
2014 Stock Incentive Plan [Member] | Mr. Ruby [Member]
Awarded stock options				$ 980,000
Common stock, per share value				$ 0.20
Stock Options [Member]
Awarded stock options		$ 1,050,000
Stock options	3,680,000		600,000
Fair value of options		612,512	417,664

STOCKHOLDERS' DEFICIT (Schedu54

STOCKHOLDERS' DEFICIT (Schedule of stock option activity) (Details) - Stock Options [Member]	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Number of Shares
Stock options outstanding, beginning of period | shares	600,000
Issued | shares	3,080,000
Exercised | shares
Expired | shares
Stock options outstanding, end of period | shares	3,680,000
Stock options exercisable, end of period | shares	3,680,000
Weighted Average Remaining Life (years)
Stock options outstanding, beginning of period	9 years 9 months 18 days
Issued	10 years
Stock options outstanding, end of period	9 years 7 months 6 days
Stock options exercisable, end of period	9 years 7 months 6 days
Weighted Average Exercise Price
Stock options outstanding, beginning of period | $ / shares	$ 0.70
Issued | $ / shares	$ 0.20
Exercised | $ / shares
Expired | $ / shares
Stock options outstanding, end of period | $ / shares	$ 0.26
Stock options exercisable, end of period | $ / shares	$ 0.26

STOCKHOLDERS' DEFICIT (Schedu55

STOCKHOLDERS' DEFICIT (Schedule of Warrants activity) (Details)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Number of Shares
Warrants outstanding, beginning of period (in shares)	3,000,000
Issued (in shares)	708,334
Issuable under terms of the amended Slainte note payable	265,914
Exercised (in shares)
Expired (in shares)	(3,000,000)
Warrants outstanding, end of period (in shares)	974,248
Warrants exercisable at the end of the period (in shares)	974,248
Weighted Average Remaining Life (years)
Warrants outstanding, beginning of period	1 year
Issued	5 years
Warrants outstanding, end of period	4 years 11 months 12 days
Warrants exercisable at the end of the period	4 years 11 months 12 days
Weighted Average Exercise Price
Warrants outstanding, beginning of period (in dollars per share) | $ / shares	$ 12
Issued (in dollars per share) | $ / shares	$ 0.18
Exercised (in dollars per share) | $ / shares
Expired (in dollars per share) | $ / shares
Warrants outstanding, end of period (in dollars per share) | $ / shares	$ 0.18
Warrants exercisable at the end of the period (in dollars per share) | $ / shares	$ 0.18

STOCKHOLDERS' DEFICIT (Common S

STOCKHOLDERS' DEFICIT (Common Stock Issued For Services and Warrants) (Details) - USD ($)	Mar. 02, 2015	Feb. 10, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Equity method investments			$ 88,000		$ 88,000
Loss on extinguishment of debt and repurchase of warrants				$ (768,602)
Issuance of Stock and Warrants for Services or Claims			$ 46,382	$ 42,600
Independent Contractor [Member]
Number of shares of common stock issued for services	30,000
Value of shares of common stock issued for services	$ 42,600
Issuance of Stock and Warrants for Services or Claims	$ 42,600
Typenex Co Investment Llc [Member] | Warrant [Member]
Number of shares of common stock issued for services		621,000
Value of shares of common stock issued for services		$ 987,390
Number of warrants issued to purchase shares of common stock		170,044
Fair value of Warrant		$ 218,788
Loss on extinguishment of debt and repurchase of warrants		$ 768,602

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based compensation expense - shares issued for consulting services	$ 46,382	$ 42,600
Share-based compensation expense - amortization of shares issued for prepaid services		66,437
Share-based compensation expense - accrual of estimated share-based awards		105,000
Share-based compensation	$ 46,382	$ 214,037

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	May. 06, 2014	Feb. 20, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Consultancy Agreement [Member]
Long-term Purchase Commitment [Line Items]
Agreement, term	9 months
Total payments	$ 200,000
Initial payment	50,000
Additional payment	$ 50,000
Shares issued for agreement	100,000
Research and development				$ 0	$ 160,000
Accrued expenses				$ 110,000	$ 110,000
Expenses recognized			$ 46,382
Percentage of completion					80.00%
Consulting Agreement [Member]
Long-term Purchase Commitment [Line Items]
Agreement, term		12 months
Warrant term		5 years
Initial payment		$ 7,500
Shares issued for agreement		250,000
Common stock, price per share		$ 0.18

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - USD ($)	Apr. 06, 2016	Dec. 30, 2016	Apr. 30, 2016	Sep. 30, 2016
JSJ Investments Inc. [Member]
Subsequent Event [Line Items]
Repayment of principal and accrued interest			$ 102,000
Slainte [Member]
Subsequent Event [Line Items]
Proceeds from debt, net	$ 75,000
Repayment of principal and accrued interest	$ 102,000
Ernest Blackmon [Member]
Subsequent Event [Line Items]
Proceeds from debt, net			25,000
Tony Verzura [Member]
Subsequent Event [Line Items]
Proceeds from debt, net			$ 25,000
Forecast [Member]
Subsequent Event [Line Items]
Interest rate (as a percent)		12.00%		22.00%
Number of trading days		10 days
Average closing price of common stock		$ 0.45
Forecast One [Member]
Subsequent Event [Line Items]
Interest rate (as a percent)				27.00%